JP2013523743A5 - - Google Patents

Info

Publication number

JP2013523743A5

JP2013523743A5 JP2013502698A JP2013502698A JP2013523743A5 JP 2013523743 A5 JP2013523743 A5 JP 2013523743A5 JP 2013502698 A JP2013502698 A JP 2013502698A JP 2013502698 A JP2013502698 A JP 2013502698A JP 2013523743 A5 JP2013523743 A5 JP 2013523743A5

Authority

JP

Japan

Prior art keywords

composition

individual

albumin

nanoparticles

taxane

Prior art date

2011-03-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims description 52
• 238000000034 method Methods 0.000 claims description 49
• 239000003814 drug Substances 0.000 claims description 48
• 229940123237 Taxane Drugs 0.000 claims description 35
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 35
• 239000002105 nanoparticle Substances 0.000 claims description 34
• 102000009027 Albumins Human genes 0.000 claims description 25
• 108010088751 Albumins Proteins 0.000 claims description 25
• 229940124597 therapeutic agent Drugs 0.000 claims description 25
• 206010028980 Neoplasm Diseases 0.000 claims description 24
• 229940079593 drug Drugs 0.000 claims description 23
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 22
• 210000001519 tissue Anatomy 0.000 claims description 22
• 201000011510 cancer Diseases 0.000 claims description 15
• 239000003795 chemical substances by application Substances 0.000 claims description 11
• 229910052697 platinum Inorganic materials 0.000 claims description 11
• 210000004027 cell Anatomy 0.000 claims description 10
• 201000010099 disease Diseases 0.000 claims description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
• 206010060862 Prostate cancer Diseases 0.000 claims description 7
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
• 230000000340 anti-metabolite Effects 0.000 claims description 7
• 229940100197 antimetabolite Drugs 0.000 claims description 7
• 239000002256 antimetabolite Substances 0.000 claims description 7
• 201000005202 lung cancer Diseases 0.000 claims description 7
• 208000020816 lung neoplasm Diseases 0.000 claims description 7
• 102000003727 Caveolin 1 Human genes 0.000 claims description 6
• 108090000026 Caveolin 1 Proteins 0.000 claims description 6
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
• 229960003668 docetaxel Drugs 0.000 claims description 6
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 6
• 229960004618 prednisone Drugs 0.000 claims description 6
• 206010027406 Mesothelioma Diseases 0.000 claims description 5
• 229930012538 Paclitaxel Natural products 0.000 claims description 5
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
• 201000001441 melanoma Diseases 0.000 claims description 5
• 229960001592 paclitaxel Drugs 0.000 claims description 5
• 201000002528 pancreatic cancer Diseases 0.000 claims description 5
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
• 239000002245 particle Substances 0.000 claims description 5
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
• 101000773038 Human herpesvirus 7 (strain RK) U21 glycoprotein Proteins 0.000 claims description 3
• 206010016629 fibroma Diseases 0.000 claims description 3
• 239000011159 matrix material Substances 0.000 claims description 3
• 206010009944 Colon cancer Diseases 0.000 claims description 2
• 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
• 230000004043 responsiveness Effects 0.000 claims description 2
• 150000003431 steroids Chemical class 0.000 claims description 2
• 210000002536 stromal cell Anatomy 0.000 claims description 2
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
• 230000003352 fibrogenic effect Effects 0.000 description 4
• 210000002435 tendon Anatomy 0.000 description 4
• 229960004562 carboplatin Drugs 0.000 description 3
• 190000008236 carboplatin Chemical compound 0.000 description 3
• 229960004316 cisplatin Drugs 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 230000003176 fibrotic effect Effects 0.000 description 2
• -1 for example Substances 0.000 description 2
• 201000010260 leiomyoma Diseases 0.000 description 2
• 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 229940079156 Proteasome inhibitor Drugs 0.000 description 1
• 206010046798 Uterine leiomyoma Diseases 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 239000003207 proteasome inhibitor Substances 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1